Literature DB >> 16906553

Issues in the use of adaptive clinical trial designs.

Scott S Emerson1.   

Abstract

Sequential sampling plans are often used in the monitoring of clinical trials in order to address the ethical and efficiency issues inherent in human testing of a new treatment or preventive agent for disease. Group sequential stopping rules are perhaps the most commonly used approaches, but in recent years, a number of authors have proposed adaptive methods of choosing a stopping rule. In general, such adaptive approaches come at a price of inefficiency (almost always) and clouding of the scientific question (sometimes). In this paper, I review the degree of adaptation possible within the largely prespecified group sequential stopping rules, and discuss the operating characteristics that can be characterized fully prior to collection of the data. I then discuss the greater flexibility possible when using several of the adaptive approaches receiving the greatest attention in the statistical literature and conclude with a discussion of the scientific and statistical issues raised by their use. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2006        PMID: 16906553     DOI: 10.1002/sim.2626

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

1.  Exploring the benefits of adaptive sequential designs in time-to-event endpoint settings.

Authors:  Sarah C Emerson; Kyle D Rudser; Scott S Emerson
Journal:  Stat Med       Date:  2010-12-29       Impact factor: 2.373

2.  HIV-1 vaccines and adaptive trial designs.

Authors:  Lawrence Corey; Gary J Nabel; Carl Dieffenbach; Peter Gilbert; Barton F Haynes; Margaret Johnston; James Kublin; H Clifford Lane; Giuseppe Pantaleo; Louis J Picker; Anthony S Fauci
Journal:  Sci Transl Med       Date:  2011-04-20       Impact factor: 17.956

Review 3.  Designing tomorrow's vaccines.

Authors:  Gary J Nabel
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

4.  Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095.

Authors:  Li Li; Joseph J Eron; Heather Ribaudo; Roy M Gulick; Brent A Johnson
Journal:  J Am Stat Assoc       Date:  2012-07-24       Impact factor: 5.033

5.  A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.

Authors:  Peter B Gilbert; Douglas Grove; Erin Gabriel; Ying Huang; Glenda Gray; Scott M Hammer; Susan P Buchbinder; James Kublin; Lawrence Corey; Steven G Self
Journal:  Stat Commun Infect Dis       Date:  2011-10

6.  Estimation and testing in targeted goup sequential covariate-adjusted randomized clinical trials.

Authors:  A Chambaz; M J van der Laan
Journal:  Scand Stat Theory Appl       Date:  2013-05-07       Impact factor: 1.396

Review 7.  Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov.

Authors:  Laura E Bothwell; Jerry Avorn; Nazleen F Khan; Aaron S Kesselheim
Journal:  BMJ Open       Date:  2018-02-10       Impact factor: 2.692

8.  Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome.

Authors:  Babak Choodari-Oskooei; Mahesh K B Parmar; Patrick Royston; Jack Bowden
Journal:  Trials       Date:  2013-01-23       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.